Avenue Therapeutics Inc., of New York, a Fortress Biotech Inc. company, has filed form 10 with the SEC in order to become a reporting company. The focus of the specialty pharma is to acquire or in-license products principally for use in the acute health care or hospital setting. Avenue's lead product candidate is an intravenous formulation of tramadol HCI for the treatment of moderate to moderately severe post-operative pain. In its filing the company said it plans to initiate a phase III development program of IV tramadol for the management of post-operative pain in 2016 following a pharmacokinetics study.

Immunocellular Therapeutics Ltd., of Calabasas, Calif., has filed form S-3 shelf prospectus with the SEC in order to raise from time to time up to $50 million by offering shares of common stock and preferred stock, debt securities and/or warrants.

Oryzon Genomics SA, of Barcelona, Spain, said it was granted two unsecured 10-year concessional loans from Spain`s Ministry of Economy and Competitiveness and will receive approximately $1.3 million (multiyear disbursements) for further development of its epigenetic inhibitors against neurodegenerative and oncologic indications. The loans will cover the funding of two 34-month projects – one, with a budget of approximately $1.1 million, encompasses further investigations of the role of ORY-2001 and other compounds in various neurological disorders, such as Huntington's disease. The other loan will be used to explore the role of new inhibitors directed to epigenetic targets other than LSD1 in cancer. The project will also examine the potential synergies of new epigenetic inhibitors with Adenosine receptor antagonists.